Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NSV0001
- Development stage
- Phase 1
- Lead developer
- Nitto
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Sublingual
01
Overview
NSV0001 is a quadrivalent influenza vaccine candidate developed for sublingual administration. It utilizes a novel adjuvant (ND002) and is designed to induce immunity against four strains of influenza virus. The vaccine is based on recombinant protein technology targeting the hemagglutinin (HA) antigen, aiming to provide broad protection against seasonal influenza. The primary developer of this vaccine is Nitto Denko Corporation. Clinical trials have evaluated its safety and immunogenicity in healthy adults[2][7].
02
Targets
HA0 (Influenza B virus hemagglutinin)HA (Hemagglutinin)
Beyond the preview
Go deeper on NSV0001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NSV0001.